Robust antitumor effects of combined anti-CD4-depleting antibody and anti-PD-1/PD-L1 immune checkpoint antibody treatment in mice

Cancer Immunology Research

Volumn 3, Issue 6, 2015, Pages 631-640

  Ueha, Satoshi ^a   Yokochi, Shoji ^a,b   Ishiwata, Yoshiro ^a,b   Ogiwara, Haru ^a   Chand, Krishant ^a   Nakajima, Takuya ^a   Hachiga, Kosuke ^a,b   Shichino, Shigeyuki ^a   Terashima, Yuya ^a   Toda, Etsuko ^a   Shand, Francis H W ^c   Kakimi, Kazuhiro ^d   Ito, Satoru ^a,b   Matsushima, Kouji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b IDAC Theranostics Inc   (Japan)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 DEPLETING MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BTLA; MONOCLONAL ANTIBODY CTLA 4; MONOCLONAL ANTIBODY GITR; MONOCLONAL ANTIBODY LAG 3; MONOCLONAL ANTIBODY OX40; MONOCLONAL ANTIBODY PD 1; MONOCLONAL ANTIBODY PDL 2; MONOCLONAL ANTIBODY PDL1; MONOCLONAL ANTIBODY TIM 3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD4 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER SIZE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; COLON CARCINOMA; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOLOGY; IN VIVO STUDY; LEUKOCYTE; LEWIS CARCINOMA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MELANOMA; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION; T CELL DEPLETION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; CYTOTOXICITY; DENDRITIC CELL; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL MELANOMA; HUMAN; IMMUNOLOGY; LYMPH NODE; LYMPHOCYTE DEPLETION; MALE; METABOLISM; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTIGENS, CD4; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HUMANS; LYMPH NODES; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA, EXPERIMENTAL; MICE; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 84961989831     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0190     Document Type: Article

References (36)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
2. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comesofage. J Clin Oncol 2011;29:4828-36.
3. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
4. Whiteside TL. Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother 2012;61:283-8.
5. Alizadeh D, Larmonier N. Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Cancer Res 2014;74:2663-8.
6. Camisaschi C, De Filippo A, Beretta V, Vergani B, Villa A, Vergani E, et al. Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. J Invest Dermatol 2014;134:1893-902.
7. Matta BM, Castellaneta A, Thomson AW. Tolerogenic plasmacytoid DC. European J Immunol 2010;40:2667-76.
8. Nagai H, Hara I, Horikawa T, Fujii M, Kurimoto M, Kamidono S, et al. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Cancer Invest 2000;18:206-13.
9. Nagai H, Hara I, Horikawa T, Oka M, Kamidono S, Ichihashi M. Elimination of CD4 (+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. J Invest Dermatol 2000;115:1059-64.
10. den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts. Cancer Res 2005;65:6984-9.
11. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201:779-91.
12. Choi BK, Kim YH, Kang WJ, Lee SK, Kim KH, Shin SM, et al. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res 2007;67:8891-9.
13. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H, et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008;132:487-98.
14. Ueha S, Yoneyama H, Hontsu S, Kurachi M, Kitabatake M, Abe J, et al. CCR7 mediates the migration of Foxp3+ regulatory T cells to the paracortical areas of peripheral lymph nodes through high endothelial venules. J Leukoc Biol 2007;82:1230-8.
15. Ueha S, Murai M, Yoneyama H, Kitabatake M, Imai T, Shimaoka T, et al. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preservinggraft-versus-tumor effects. J Leukoc Biol 2007;81:176-85.
16. Shono Y, Ueha S, Wang Y, Abe J, Kurachi M, Matsuno Y, et al. Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. Blood 2010;115:5401-11.
17. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008;111:5457-66.
18. Shand FH, Ueha S, Otsuji M, Koid SS, Shichino S, Tsukui T, et al. Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes. ProcNatl Acad Sci U S A 2014;111:7771-6.
19. Anderson KG, Mayer-Barber K, Sung H, Beura L, James BR, Taylor JJ, et al. Intravascular staining for discrimination of vascular and tissue leukocytes. Nat Protoc 2014;9:209-22.
20. Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res 2014;20:44-55.
21. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-80.
22. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity 2008;29:848-62.
23. Sakaguchi S. Regulatory T cells: history and perspective. Methods Mol Biol 2011;707:3-17.
24. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med 2002;8:793-800.
25. Furuta J, Inozume T, Harada K, Shimada S. CD271 on melanoma cell is an IFN-gamma-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. J Invest Dermatol 2014;134:1369-77.
26. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342:1432-3.
27. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
28. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24:207-12.
29. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
30. Predina J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci U S A 2013;110:E415-24.
31. Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M, et al. Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFN-gammadependent cell-cycle arrest. Cancer Immunol Res 2015;3:26-36.
32. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013;494:361-5.
33. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999;59:3128-33.
34. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-8.
35. Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109:4655-62.
36. Rider DA, Havenith CE, de Ridder R, Schuurman J, Favre C, Cooper JC, et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res 2007;67:9945-53.